Biotechnology Company
Appears in 1 story · Last updated Aug 15, 2026
As of August 2026: Awaiting EMA review outcome after MAA validation; reaffirmed 2026 sales guidance of 135-150 million euros in its August 13 earnings update
The vaccine, now formally designated PF-07307405 (also called LB6V, and previously known as VLA15), cleared its first regulatory hurdle since March's Phase 3 results. On August 14, 2026, the European Medicines Agency validated Pfizer and Valneva's marketing application, meaning the dossier is complete and formal review can begin.
Updated Aug 15
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
